Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atazanavir - Bristol-Myers Squibb

Drug Profile

Atazanavir - Bristol-Myers Squibb

Alternative Names: Atazanavir sulfate; Atazor; BMS-232632; BMS-232632-05; CGP 73547; Reyataz; TAZ

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Bristol-Myers Squibb; Emcure Pharmaceuticals; Gilead Sciences
  • Class Antiretrovirals; Oligopeptides; Pyridines; Small molecules
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Sep 2017 Bristol-Myers Squibb completes the phase III PRINCE1 trial for HIV-1 Infections (In children, In infants, Combination therapy) in Brazil, Chile, Mexico, Peru, South Africa and Thailand, Italy and Poland (PO, Powder) (NCT01099579)
  • 10 May 2017 Bristol-Myers Squibb completes the phase III PRINCE2 trial for HIV-1 Infections (In children, In infants, Combination therapy) in USA, Argentina, Brazil, Chile, Mexico, South Africa, United Kingdom, Poland, Romania, Spain and Russia (PO) (NCT01335698)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top